Sumitomo Mitsui Trust Group Inc. Grows Stock Position in Insulet Corporation $PODD

Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 3.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 166,454 shares of the medical instruments supplier’s stock after purchasing an additional 5,450 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.24% of Insulet worth $34,929,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. State Street Corp boosted its stake in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after buying an additional 65,317 shares during the period. Geode Capital Management LLC raised its holdings in Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares in the last quarter. Invesco Ltd. raised its holdings in Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after acquiring an additional 141,167 shares in the last quarter. Norges Bank purchased a new position in Insulet in the fourth quarter worth approximately $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Insulet by 3.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock worth $229,131,000 after acquiring an additional 29,690 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PODD. Piper Sandler dropped their price objective on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Sanford C. Bernstein decreased their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. BTIG Research dropped their price objective on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, May 26th. Oppenheimer dropped their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. decreased their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $235.25.

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.36% of the stock is currently owned by company insiders.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Several firms, including Rosen, Robbins, Schall, Bronstein, and BFA Law, issued fresh notices about a securities class action against Insulet, highlighting alleged misrepresentations and safety issues tied to Omnipod devices and a defective cannula manufacturing claim. Article Title
• Negative Sentiment: The class-action filings may increase legal costs, management distraction, and uncertainty around potential damages, all of which can pressure investor sentiment toward Insulet. Article Title
• Neutral Sentiment: Royal Bank of Canada lowered its price target on Insulet from $280 to $245 but kept an outperform rating, signaling continued optimism even as analysts trimmed expectations. Article Title
• Neutral Sentiment: Commentary from market coverage suggested PODD also moved with broader medtech weakness, indicating some of the recent share-price pressure may be sector-related rather than company-specific. Article Title

Insulet Stock Performance

NASDAQ PODD opened at $162.06 on Tuesday. The firm has a market cap of $11.22 billion, a P/E ratio of 37.69, a P/E/G ratio of 1.12 and a beta of 1.11. Insulet Corporation has a 52-week low of $138.79 and a 52-week high of $354.88. The business’s 50-day moving average price is $152.73 and its 200 day moving average price is $209.90. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period last year, the firm earned $1.02 EPS. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.